Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Carcinoma
|
2793 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.040 | 1.000 | 4 | 2012 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.040 | 1.000 | 4 | 2012 | 2018 | |||||
Carcinoma of lung
|
1204 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Malignant neoplasm of lung
|
1142 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Primary malignant neoplasm of lung
|
981 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.030 | 1.000 | 3 | 2011 | 2018 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.020 | 1.000 | 2 | 2011 | 2015 | |||||
Adenoma of large intestine
|
213 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Adult Lymphoma
|
66 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1 | 2013 | 2013 | ||||||
Central neuroblastoma
|
231 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Childhood Lymphoma
|
66 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1 | 2013 | 2013 | ||||||
Childhood Neuroblastoma
|
231 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Lymphoma
|
91 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1 | 2013 | 2013 | ||||||
MYELODYSPLASTIC SYNDROME
|
95 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1 | 2017 | 2017 | ||||||
Neoplasms
|
1644 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Neuroblastoma
|
386 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
progesterone receptor-negative breast cancer
|
11 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
progesterone receptor-positive breast cancer
|
17 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Squamous cell carcinoma
|
257 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Xeroderma pigmentosum, group A
|
55 | 0.701 | 0.360 | 9 | 97697296 | 5 prime UTR variant | T/C;G | snv | 0.63; 4.5E-06; 4.5E-06 | 0.010 | 1.000 | 1 | 2018 | 2018 |